{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:00:49Z","timestamp":1791658849236,"version":"4.3.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Resverlogix"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40256-017-0250-3","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T01:26:14Z","timestamp":1507771574000},"page":"109-115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease"],"prefix":"10.1007","volume":"18","author":[{"given":"Stephen J.","family":"Nicholls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan O.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Kulikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"key":"250_CR1","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","volume":"46","author":"P Libby","year":"2005","unstructured":"Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46:1225\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"250_CR2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross R. Atherosclerosis\u2014an inflammatory disease. N Engl J Med. 1999;340:115\u201326.","journal-title":"N Engl J Med"},{"key":"250_CR3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20\u20138.","journal-title":"N Engl J Med"},{"key":"250_CR4","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1097\/01.hjh.0000178835.33976.e7","volume":"23","author":"C Catena","year":"2005","unstructured":"Catena C, Novello M, Lapenna R, et al. New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a). J Hypertens. 2005;23:1617\u201331.","journal-title":"J Hypertens"},{"key":"250_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ddtec.2016.09.001","volume":"19","author":"J Meslamani","year":"2016","unstructured":"Meslamani J, Smith SG, Sanchez R, Zhou MM. Structural features and inhibitors of bromodomains. Drug Discov Today Technol. 2016;19:3\u201315.","journal-title":"Drug Discov Today Technol"},{"key":"250_CR6","doi-asserted-by":"crossref","first-page":"e83190","DOI":"10.1371\/journal.pone.0083190","volume":"8","author":"KG McLure","year":"2013","unstructured":"McLure KG, Gesner EM, Tsujikawa L, et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One. 2013;8:e83190.","journal-title":"PLoS One"},{"key":"250_CR7","doi-asserted-by":"crossref","unstructured":"Wasiak S, Gilham D, Tsujikawa LM et al. Downregulation of the complement cascade in vitro, in mice and in patients with cardiovascular disease by the BET protein inhibitor apabetalone (RVX-208). J Cardiovasc Transl Res. 2017.","DOI":"10.1007\/s12265-017-9755-z"},{"key":"250_CR8","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.dib.2016.07.047","volume":"8","author":"S Wasiak","year":"2016","unstructured":"Wasiak S, Gilham D, Tsujikawa LM, et al. Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes. Data Brief. 2016;8:1280\u20138.","journal-title":"Data Brief"},{"key":"250_CR9","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.jacc.2010.02.035","volume":"55","author":"D Bailey","year":"2010","unstructured":"Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010;55:2580\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"250_CR10","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.5114\/aoms.2016.62906","volume":"12","author":"BA Bartolo Di","year":"2016","unstructured":"Di Bartolo BA, Scherer DJ, Nicholls SJ. Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond. Arch Med Sci: AMS. 2016;12:1302\u20137.","journal-title":"Arch Med Sci: AMS"},{"key":"250_CR11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jacc.2010.11.015","volume":"57","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, Gordon A, Johansson J, et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011;57:1111\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"250_CR12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40256-015-0146-z","volume":"16","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Wolski K, et al. Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE Trial. Am J Cardiovasc Drug. 2016;16:55\u201365.","journal-title":"Am J Cardiovasc Drug"},{"key":"250_CR13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2016.01.036","volume":"247","author":"D Gilham","year":"2016","unstructured":"Gilham D, Wasiak S, Tsujikawa LM, et al. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I\/HDL and represses pathways that contribute to cardiovascular disease. Atherosclerosis. 2016;247:48\u201357.","journal-title":"Atherosclerosis"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-017-0250-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-017-0250-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-017-0250-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T09:00:49Z","timestamp":1521018049000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-017-0250-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["250"],"URL":"https:\/\/doi.org\/10.1007\/s40256-017-0250-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,12]]}}}